Trial Profile
The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer): A Multinational, Randomized, Open-label Phase 3 Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary, Fallopian Tube or Primary Peritoneum
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 01 Nov 2023
Price :
$35
*
At a glance
- Drugs Binimetinib (Primary) ; Doxorubicin liposomal; Paclitaxel; Topotecan
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Registrational; Therapeutic Use
- Acronyms MILO
- Sponsors Array BioPharma; Pfizer
- 26 Oct 2023 Status changed from completed to discontinued.
- 15 Aug 2023 Results of the post-hoc tumor tissue biomarker analysis of this study, published in the Clinical Cancer Research.
- 01 Nov 2022 Status changed from active, no longer recruiting to completed.